Nurix Therapeutics, Inc. (NRIX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $16.57: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 2.72; Below-average business quality.
Nurix Therapeutics is a clinical-stage biopharma using AI-integrated protein degradation technology to develop oncology and inflammatory disease treatments. Its three wholly owned clinical assets -- bexobrutideg (Phase 2 pivotal in CLL), zelebrudomide (Phase 1 in B-cell... Read more
Sell if holding. Engine safety override at $16.57: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 2.72; Below-average business quality. Chart setup: RSI 55 mid-range, Bollinger mid-band. Score 4.2/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.75, earnings proximity 70d clear, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinebexobrutideg10-K Item 1A: 'Our lead drug candidates, bexobrutideg, zelebrudomide and NX-1607, are in the early stages of clinical development and their risk of failure is high.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.57: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 2.72; Below-average business quality. Chart setup: RSI 55 mid-range, Bollinger mid-band. Prior stop was $15.41. Score 4.2/10, moderate confidence.
Take-profit target: $27.21 (+64.2% upside). Prior stop was $15.41. Stop-loss: $15.41.
Concentration risk — Pipeline: bexobrutideg; Quality below floor (1.9 < 4.0); Value-trap signals (2/5): Margin compression (op margin -3.4%), Material insider selling (104 sells, 0.27% of cap).
Nurix Therapeutics, Inc. trades at a P/E of N/A (forward -5.8). TrendMatrix value score: 5.4/10. Verdict: Sell.
23 analysts cover NRIX with a consensus score of 4.3/5. Average price target: $30.
What does Nurix Therapeutics, Inc. do?Nurix Therapeutics is a clinical-stage biopharma using AI-integrated protein degradation technology to develop oncology...
Nurix Therapeutics is a clinical-stage biopharma using AI-integrated protein degradation technology to develop oncology and inflammatory disease treatments. Its three wholly owned clinical assets -- bexobrutideg (Phase 2 pivotal in CLL), zelebrudomide (Phase 1 in B-cell malignancies), and NX-1607 (Phase 1) -- are partnered with Gilead, Sanofi, and Pfizer for additional targets.